Pay in 4 interest-free payments of $6.19 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Phase 3 data from the TRIUMPH-4 trial showed an average of 28.7% body weight reduction at the 12 mg dose over 68 weeks
Preclinical and early clinical findings indicate potential for supporting investigations into: Improved lean body mass and protein synthesis Enhanced recovery and cellular repair mechanisms Age-related changes in growth hormone secretion While these findings are promising, it is important to emphasize that these compounds are strictly for laboratory and scientific research
Metabolic Health Improvements Beyond Weight Weight loss medications in this class produce benefits that extend well beyond the number on the scale
Following the patent expiry in March 2026, more than 50 generic semaglutide products approved by the Central Drugs Standard Control Organisation (CDSCO) entered the market from companies including Natco Pharma, Zydus Lifesciences, Alkem Laboratories, Sun Pharma, Glenmark Pharmaceuticals, Dr
J Biol Chem 277(4):26872694
US$ 21.38
US$ 23.57
US$ 26.07
US$ 23.40
